通过EVs介导的CB2受体激活剂用于阿尔茨海默氏症治疗
Yanjing Zhu1,2, Ruiqi Huang1, Deheng Wang3
1Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopaedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai 200065, China.
载有AM1241 (EVs-AM1241) 的介质干细胞衍生外细胞囊泡对阿尔茨海默氏症 (AD) 有望出现. 在AD模型小鼠中,EVs-AM1241改善了记忆力,减少了粉样质斑块,并促进了神经元再生.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其机制不清楚,治疗选择有限.
- 神经元退化和认知能力下降是AD进展的标志.
研究的目的:
- 为了研究带有AM1241 (EVs-AM1241) 的中酶体干细胞衍生细胞外囊的治疗潜力,用于阿尔茨海默病.
- 评估EVs-AM1241在改善AD模型小鼠的神经元功能和逆转神经退行性病理方面的疗效.
主要方法:
- 电动汽车-AM1241.1.的构造和特征.
- 使用莫里斯水迷宫和恐惧调节测试评估学习和记忆.
- 在体内,电生理学记录,免疫染色,西斑和RNA测序用于分析分子和细胞变化.
主要成果:
- 与裸体AM1241.1相比,EVs-AM1241的生物可用性和治疗效果得到了提高.
- 在接受EVs-AM1241治疗的小鼠中观察到学习和记忆的显著改善.
- EVs-AM1241抑制了粉样蛋白斑沉积,减少了粉样蛋白β诱导的神经细胞亡,增加了神经元数量,并恢复了神经元细胞骨架.
结论:
- 在AD模型小鼠中,EVs-AM1241有效地逆转了神经退行性病理,并增强了神经发生.
- 治疗促进了Aβ细胞和通过-Erk信号通路改善了认知功能.
- EVs-AM1241代表了阿尔茨海默病治疗的有前途的治疗策略.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
